Moderna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year.3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV...
Source LinkModerna's stock is undervalued, so I maintain a positive outlook with a $97 price target for next year.3Q24 results show good COVID-19 revenue, cost efficiency, and a significant cash balance, but RSV...
Source Link
Comments